Antibiotic Resistance and Superbug Threat: Public Health Challenge for Bangladesh

The Antibiotic That No Longer Works

A child in Dhaka is admitted to hospital with a bloodstream infection. The attending physician prescribes ciprofloxacin — a fluoroquinolone antibiotic that has been a first-line treatment for bacterial infections for decades. The drug fails. A second antibiotic is tried. It fails too. The physician moves to a third-line treatment, more expensive and harder to obtain. The infection, meanwhile, has time to worsen. This scenario, once a clinical rarity, is becoming increasingly common in Bangladesh's hospitals and diagnostic centers — a ground-level manifestation of what global health authorities have begun calling the silent pandemic of antimicrobial resistance.

Antimicrobial resistance, or AMR, describes the process by which bacteria, viruses, fungi and parasites evolve to withstand the drugs designed to kill them. The consequence is infections that become progressively harder — and eventually impossible — to treat with available medicines. The World Health Organization designated AMR one of the top global public health and development threats. The evidence increasingly suggests that Bangladesh, positioned squarely in the South Asia region forecast to bear the highest AMR mortality burden in the world, is facing a public health crisis it has not yet fully mobilized to address.

The Global Numbers: Three Deaths Every Minute by 2050

The landmark Global Research on Antimicrobial Resistance (GRAM) Project study published in The Lancet in September 2024 produced the most comprehensive analysis of AMR burden ever conducted — covering 204 countries and territories from 1990 to 2021, with forecasts to 2050. The findings are stark. Antibiotic resistance has claimed at least one million lives every year since 1990 — a cumulative toll exceeding 36 million deaths over three decades. Without further intervention, AMR is forecast to directly cause 39 million deaths between 2025 and 2050, the equivalent of three deaths per minute. Annual AMR-attributable deaths are projected to rise from 1.14 million in 2021 to 1.91 million by 2050 — an increase of nearly 70 percent.

The geography of this forecast is the most significant finding for Bangladesh. South Asia — including India, Pakistan, and Bangladesh — is projected to experience 11.8 million AMR-attributable deaths between 2025 and 2050, the highest regional burden in the world. WHO's October 2025 Global Antibiotic Resistance Surveillance Report, the most comprehensive picture yet based on data from over 100 countries, found that one in three infections in the WHO South-East Asia Region was resistant to antibiotics. In the same report, WHO Director-General Tedros Adhanom Ghebreyesus warned that AMR is outpacing advances in modern medicine.

The economic dimension compounds the mortality forecast. AMR contributes to estimated GDP losses of $1 to $3.4 trillion per year globally by 2030. Across human history, AMR's resistance to economic analysis has been part of what makes it politically difficult to address: the costs are diffuse, accumulate slowly, and materialize most severely in future decades — while the short-term commercial incentives driving antibiotic overuse generate immediate profit.

Bangladesh's AMR Landscape: The Specific Vulnerabilities

Bangladesh faces a convergence of drivers that makes it particularly exposed to the AMR crisis. Research from the CHIRAL Bangladesh Health Data Science Lab, published in January 2025 in Health Science Reports, identifies several interconnected factors: widespread availability of antibiotics without prescription, irrational use in both human healthcare and food animal production, a growing trend of self-medication, and environmental contamination from pharmaceutical manufacturing and hospital effluent.

A retrospective study published in the American Journal of Clinical Pathology in November 2025 — analyzing 925 culture-positive specimens from a Dhaka diagnostic center across all of 2024 — documented rising resistance to first-line antibiotics including ciprofloxacin (fluoroquinolones), azithromycin, and beta-lactams. These are not obscure or last-resort drugs. They are the antibiotics that Bangladesh's healthcare system reaches for first when treating common bacterial infections: urinary tract infections, respiratory infections, wound infections, typhoid. Resistance to these first-line treatments means patients progress faster to second and third-line options — drugs that are costlier, often less available outside Dhaka, and carry greater side effects.

A 2025 study from Jahangirnagar University, published in npj Clean Water, screened 155 enteric bacterial isolates from eight different water sources in Dhaka and found that antimicrobial-resistant and multidrug-resistant bacteria were widely distributed. Water sources with direct exposure to antibiotics — from pharmaceutical plant runoff and hospital discharge — showed significantly higher frequencies of resistance. The study's finding that resistance genes in freshwater samples resembled those from clinical isolates is particularly troubling: it suggests that Bangladesh's water environment is functioning as a reservoir for resistance genes that circulate back into human populations through contaminated water consumption.

Bangladesh's poultry sector adds another layer of risk. Research on broiler chickens in Sylhet district, published in Veterinary Medicine and Science in 2025, found that antibiotic use in poultry farming remains largely unregulated — antibiotics can be purchased without veterinary prescriptions — and that multidrug-resistant E. coli strains were widely present. These strains can be transmitted from animals to humans through direct contact, environmental contamination, and consumption of contaminated meat and eggs. In a country where poultry is a primary protein source across all income groups, the food-chain transmission pathway for AMR is not theoretical. It is active.

Over-the-Counter Antibiotics: The Structural Driver

At the center of Bangladesh's AMR problem is a practice so normalized it barely registers as a policy failure: the sale of antibiotics without a prescription. Research studies, government reports, and clinical observations consistently identify this as the primary structural driver of resistance in Bangladesh. A study found that 60 percent of people in Bangladesh's hill tracts were consuming antibiotics without a doctor's advice — purchasing drugs including for headaches from pharmacies and shops that sell antibiotics without appearing to know or enforce the legal requirement for a prescription.

Bangladeshi newspapers' coverage of AMR between 2010 and 2021 — analyzed in a PLOS One study published in May 2024 — found that consumer misuse was the most reported driver (32.2 percent of coverage), followed by selling without prescriptions (29 percent) and over-prescription by health providers (26.1 percent). Yet the study noted that most coverage was event-driven and reactive, rather than sustained investigative or public education journalism. AMR rarely generated its own media cycle; it surfaced when a senior official gave a speech or a WHO report was released.

The legal framework exists. Bangladesh's Drug Control Ordinance prohibits antibiotic sales without prescription, and the government enacted a National Action Plan for AMR in 2017 covering human health, animal health, and environmental sectors. But implementation has lagged significantly. The Directorate General of Health Services has been unable to monitor nationwide progress due to field-level operational failures. Regulatory enforcement of pharmacy practice remains inconsistent, and drug sellers in many areas are unaware that the products they're selling require prescriptions.

Inside Dhaka's Hospitals: What Clinicians Are Seeing

At clinical level, AMR's progression in Bangladesh is visible in the changing pattern of treatment failures. The 2025 Dhaka study documenting rising ciprofloxacin and azithromycin resistance in clinical isolates reflects what clinicians have observed across the country's tertiary hospitals: empiric antibiotic therapy — prescribing a drug based on likely pathogens before culture results return — is increasingly failing because the first-line drugs chosen are resistant to the actual infecting bacteria.

Antibiotic susceptibility testing, which identifies which antibiotics remain effective against a specific bacterial isolate, requires laboratory infrastructure that is concentrated in major urban hospitals. Outside Dhaka and Chittagong's tertiary centers, many facilities lack the diagnostic capacity to guide appropriate antibiotic selection. Clinicians in district hospitals or community health centers often prescribe empirically based on clinical judgment, without any susceptibility data. In an environment of rising resistance, this means more patients receiving ineffective treatment for longer before appropriate therapy is identified — longer hospitalization, greater complications, higher mortality.

Intensive care units face the sharpest version of this challenge. Carbapenem-resistant organisms — bacteria that have developed resistance to carbapenems, a class of antibiotics considered last-resort options for the most severe infections — have been detected in Bangladeshi hospitals. When a patient in an ICU develops a carbapenem-resistant bloodstream infection, the therapeutic options narrow dramatically. Some cases are left with colistin, a drug that is itself highly toxic to kidneys and represents the last line of defense in Bangladesh's accessible pharmaceutical arsenal.

The National Action Plan: Gap Between Policy and Practice

Bangladesh's National Action Plan on AMR, developed in 2017 for the period through 2022, was aligned with the WHO global plan and addressed four pillars: rational antibiotic use through treatment guidelines and stewardship programs, development of reference laboratories, Good Manufacturing and Pharmacy Practices, and infection prevention and control. Five years later, independent assessments found that the plan's implementation remained at an early stage. Coordination between the human health, animal health, and environmental sectors — essential for the One Health approach that global experts identify as necessary for meaningful AMR control — has been limited. Laboratory capacity for AMR surveillance outside major centers has not grown at the pace the problem demands.

The Institute of Epidemiology, Disease Control and Research has published AMR surveillance reports for Bangladesh — the 2024 edition was released in 2025 — but national surveillance coverage remains incomplete. Resistance data from rural and community settings, where much of Bangladesh's antibiotic misuse occurs and where diagnostic capacity is lowest, are systematically underrepresented. The actual burden of AMR in Bangladesh is likely substantially higher than surveillance data suggests.

What Preparedness Requires: The Path Forward

The GRAM Project's Lancet study identifies the interventions that could avert the worst outcomes. In the "better care" scenario, improved quality of healthcare for severe infections and expanded access to appropriate antibiotics could cumulatively avert 92 million deaths globally between 2025 and 2050 — with South Asia among the regions that would benefit most, potentially averting 31.7 million deaths. In the "new drugs" scenario, development of a pipeline of antibiotics targeting Gram-negative resistant pathogens — the same E. coli and K. pneumoniae strains documented in Dhaka's hospitals and water sources — could avert an additional 11 million deaths.

For Bangladesh, translating these global scenarios into national action requires movement on several fronts simultaneously. Pharmacy regulation enforcement needs genuine investment: not periodic crackdowns on antibiotic sales, but systematic inspection, pharmacist training, and prescription verification systems that change daily practice. Antibiotic stewardship programs — where hospital teams monitor, guide, and audit antibiotic prescribing — need to expand beyond Dhaka's major tertiary centers into district and upazila level facilities. Laboratory diagnostic capacity for bacterial culture and antibiotic susceptibility testing needs to be treated as essential infrastructure, not a specialist service.

In the agricultural sector, Bangladesh needs functional enforcement of the ban on antibiotic use as growth promoters in poultry and aquaculture — a ban that exists on paper but is undermined by the absence of veterinary prescription systems, low awareness among farmers, and inadequate inspection capacity. The food-chain transmission pathway for AMR is preventable; preventing it requires institutional capacity that currently does not match the scale of the sector.

At the environmental level, the pharmaceutical manufacturing sector — Bangladesh has a significant domestic pharmaceutical industry — needs stricter effluent standards for antibiotic-containing discharge. Water treatment infrastructure in Dhaka, already under pressure from urbanization, needs upgrading capable of managing pharmaceutical contamination. The Jahangirnagar University study's finding that Dhaka's freshwater sources carry clinical-grade resistance genes is a water safety issue as much as a pharmaceutical one.

The antibiotic that no longer works in a Dhaka hospital ward is not simply a clinical problem. It is the downstream consequence of decades of unregulated access, agricultural misuse, inadequate surveillance, and deferred institutional investment. Bangladesh's position at the epicenter of the world's highest-burden AMR region means the cost of continued deferral is measured not in policy failures, but in lives. The forecasts are precise. The interventions are identified. What remains is the political and institutional will to implement them before the trajectory becomes irreversible.